Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Takeda

Status: Completed

Conditions: Hypertension

Treatments: Drug: Azilsartan

Study type: Observational

Funder types: Industry

Identifiers

NCT02092025

JapicCTI-142441 (Registry Identifier)

279-011

Details and patient eligibility

About

The purpose of this survey is to evaluate the safety and efficacy of long-term use of azilsartan tablets (Azilva Tablets) in patients with hypertension in a routine clinical setting.

Full description

This surveillance was designed to evaluate the safety and efficacy of long-term use of azilsartan tablets (Azilva Tablets) in hypertensive patients in daily medical practice.

The usual dosage for adult is 20 mg of azilsartan administered orally once daily. The dose can be adjusted according to the patient's age and condition. The maximum daily dose is 40 mg.

Enrollment: 3,437 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertensive patients

Exclusion criteria

1. Patients with a history of hypersensitivity to any of the ingredients of Azilsartan
2. Patients who are pregnant or having possibilities of being pregnant

Trial design

3,437 participants in 1 patient group

Azilsartan

Description:

Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.

Treatment:

Drug: Azilsartan